Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inmagene Biopharmaceuticals
Deal Size : $920.0 million
Deal Type : Partnership
Details : Chi-Med grants Inmagene exclusive options to four drug candidates solely for the treatment of immunological diseases. Upon exercise of the option, Inmagene will have the right to further develop, manufacture and commercialize that specific drug candidate...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 01, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inmagene Biopharmaceuticals
Deal Size : $920.0 million
Deal Type : Partnership
Lead Product(s) : Savolitinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC
Details : final analysis of savolitinib in Phase Ib TATTON study Parts B and D will be presented at the upcoming virtual 2020 World Conference on Lung Cancer (WCLC 2020).
Product Name : HMPL-504
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2021
Lead Product(s) : Savolitinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The NMPA approval of Sulanda® was based on results from the SANET-ep study. The Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS in all subgroups of non-pancreatic NET patients with an acceptab...
Product Name : Sulanda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 30, 2020
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The pivotal Phase III SANET-ep trial demonstrated surufatinib reduced risk of progression or death by 67%, extending PFS of non-pancreatic NET patients with an acceptable risk/benefit ratio.
Product Name : Sulanda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 28, 2020
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Application is based on the scientific advice which the company got from the European Medicines Agency’s Committee for Medicinal Products for Human Use for surufatinib for the treatment of patients with advanced neuroendocrine tumors.
Product Name : Sulanda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 08, 2020
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Savolitinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi® Data
Details : The CALYPSO study is an independently sponsored open-label Phase II study of Imfinzi® in combination with several drug candidates in the treatment of renal cell carcinoma in the U.K. and Spain.
Product Name : HMPL-504
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 02, 2020
Lead Product(s) : Savolitinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”).
Product Name : Sulanda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 20, 2020
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Chi-Med Announces Second NDA Acceptance in China for Surufatinib in Pancreatic Neuroendocrine Tumors
Details : The NDA is supported by data from the successful SANET-p study, a Phase III pivotal study of surufatinib in advanced neuroendocrine tumors – pancreatic patients in China for whom there is no effective therapy.
Product Name : Sulanda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 17, 2020
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020
Details : New and updated analyses on the studies of surufatinib and fruquintinib will be presented at the upcoming European Society for Medical Oncology (ESMO) Virtual Congress 2020.
Product Name : Sulanda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2020
Lead Product(s) : Surufatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fruquintinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China
Details : Under the terms of the 2020 Amendment, Lilly will maintain the exclusive commercialization rights, and as a consequence, will continue to consolidate the sales of Elunate® in China. Chi-Med will collaborate with Lilly in commercializing Elunate® acros...
Product Name : Elunate
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 28, 2020
Lead Product(s) : Fruquintinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration